ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.
Anagnostou V, Ho C, Nicholas G, Juergens RA, Sacher A, Fung AS, Wheatley-Price P, Laurie SA, Levy B, Brahmer JR, Balan A, Niknafs N, Avrutin E, Zhu L, Sausen M, Bradbury PA, O'Donnell-Tormey J, Gaudreau PO, Ding K, Dancey J.
Anagnostou V, et al. Among authors: bradbury pa.
Nat Med. 2023 Oct;29(10):2559-2569. doi: 10.1038/s41591-023-02598-9. Epub 2023 Oct 9.
Nat Med. 2023.
PMID: 37814061
Free PMC article.
Clinical Trial.